| Literature DB >> 30733836 |
Dequan Liu1, Yu Yun1,2, Dechun Yang1, Xinyu Hu1, Xianxiang Dong1, Nan Zhang1, Lumei Zhang2, Hua Yin2, Weigang Duan2.
Abstract
The main aim of the present study was to investigate the biological function of uric acid. The level of uric acid in different organs in normal male rats was determined with uric acid assay kits, and the expression level of genes in the organs was determined by RNA quantitative sequencing. The correlation analysis between uric acid in the organs and gene expression (measured by FPKM value) was made. Serum uric acid (SUA) in patients with breast cancer or with breast benign tumor was assayed when the diagnosis was made, and SUA in patients with breast cancer was also assayed just after chemotherapy. There were 1937 mRNAs whose expression level significantly correlated with the level of uric acid, and most of which were associated with purine or nucleoside metabolism, cellular metabolism, cell cycles, and cell death pathways. Further analysis showed that the level of uric acid was highly correlated with cell death rather than cell viability. The level of SUA in patients with breast cancer was higher than that in patients with breast benign tumor, and the SUA increased after chemotherapy. All the results suggested that uric acid was mainly synthesized from local nucleosides degraded from dead cells, and uric acid could be an important biomarker for cell death rather than an antioxidant for neural protection.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30733836 PMCID: PMC6348815 DOI: 10.1155/2019/4081962
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434
Figure 1Distribution of uric acid in male rat's organs (mean + SD, n = 10, data cited from our previous study [6]). Ileum: the last 5 cm of the ileum; skeletal muscle: the ectogluteus.
Figure 2Distribution of uric acid in neonatal rats (mean + SD, n = 3).
Top 20 pathways with significance could be associated with the level of uric acid in different organs.
| ID | Description | Significant | Annotated |
|
| Positive num. | Negative num. |
|---|---|---|---|---|---|---|---|
| ko03010 | Ribosome | 184/1937 | 288/7604 | 1.26E-44 | 3.37E-42 | 172 | 12 |
| ko04141 | Protein processing in the endoplasmic reticulum | 89/1937 | 172/7604 | 8.09E-14 | 1.09E-11 | 62 | 27 |
| ko00240 | Pyrimidine metabolism | 50/1937 | 106/7604 | 9.93E-07 | 8.89E-05 | 36 | 14 |
| ko04975 | Fat digestion and absorption | 24/1937 | 39/7604 | 1.99E-06 | 0.000134 | 21 | 3 |
| ko00520 | Amino sugar and nucleotide sugar metabolism | 27/1937 | 49/7604 | 8.96E-06 | 0.000481 | 19 | 8 |
| ko05110 | Vibrio cholerae infection | 28/1937 | 52/7604 | 1.11E-05 | 0.000494 | 14 | 14 |
| ko00230 | Purine metabolism | 68/1937 | 170/7604 | 1.88E-05 | 0.000721 | 38 | 30 |
| ko00480 | Glutathione metabolism | 28/1937 | 54/7604 | 2.80E-05 | 0.000941 | 21 | 7 |
| ko00983 | Drug metabolism (other enzymes) | 22/1937 | 39/7604 | 3.73E-05 | 0.001011 | 19 | 3 |
| ko03460 | Fanconi anemia pathway | 27/1937 | 52/7604 | 3.77E-05 | 0.001011 | 18 | 9 |
| ko03008 | Ribosome biogenesis in eukaryotes | 37/1937 | 81/7604 | 5.99E-05 | 0.001462 | 25 | 12 |
| ko00620 | Pyruvate metabolism | 23/1937 | 43/7604 | 7.72E-05 | 0.001727 | 10 | 13 |
| ko00330 | Arginine and proline metabolism | 28/1937 | 59/7604 | 0.000209 | 0.004278 | 17 | 11 |
| ko00500 | Starch and sucrose metabolism | 21/1937 | 40/7604 | 0.000223 | 0.004278 | 12 | 9 |
| ko03030 | DNA replication | 20/1937 | 38/7604 | 0.000301 | 0.00538 | 16 | 4 |
| ko00900 | Terpenoid backbone biosynthesis | 14/1937 | 23/7604 | 0.000342 | 0.005742 | 10 | 4 |
| ko00561 | Glycerolipid metabolism | 26/1937 | 56/7604 | 0.000534 | 0.008435 | 19 | 7 |
| ko04972 | Pancreatic secretion | 40/1937 | 98/7604 | 0.000587 | 0.008748 | 33 | 7 |
| ko04113 | Meiosis (yeast) | 26/1937 | 59/7604 | 0.001403 | 0.019819 | 19 | 7 |
| ko04111 | Cell cycle (yeast) | 29/1937 | 70/7604 | 0.002443 | 0.032791 | 24 | 5 |
| ko00970 | Aminoacyl-tRNA biosynthesis | 21/1937 | 47/7604 | 0.003207 | 0.03985 | 12 | 9 |
| ko00510 | N-Glycan biosynthesis | 22/1937 | 50/7604 | 0.003266 | 0.03985 | 19 | 3 |
| ko02020 | Two-component system | 10/1937 | 17/7604 | 0.003564 | 0.041593 | 6 | 4 |
| ko04110 | Cell cycle | 45/1937 | 123/7604 | 0.003905 | 0.043679 | 42 | 3 |
| ko04210 | Apoptosis | 33/1937 | 85/7604 | 0.004440 | 0.045337 | 21 | 12 |
| ko03440 | Homologous recombination | 14/1937 | 28/7604 | 0.004476 | 0.045337 | 10 | 4 |
| ko00100 | Steroid biosynthesis | 11/1937 | 20/7604 | 0.004560 | 0.045337 | 11 | 0 |
| ko04910 | Insulin signaling pathway | 48/1937 | 134/7604 | 0.004738 | 0.045421 | 19 | 29 |
| ko00564 | Glycerophospholipid metabolism | 35/1937 | 92/7604 | 0.005061 | 0.046841 | 23 | 12 |
| ko03060 | Protein export | 12/1937 | 23/7604 | 0.005410 | 0.048403 | 8 | 4 |
FPKM of genes mainly associated with urate metabolism and its correlation with the level of uric acid in different rat organs (mean ± SD, n = 3).
| Gene | Brain | Kidney | Lung | Liver | Heart | Stomach | Duodenum | Terminal ileum |
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| Xdh | 2.57 ± 0.19 | 35.45 ± 3.79 | 66.10 ± 11.01 | 32.08 ± 1.73 | 26.76 ± 13.90 | 18.94 ± 5.88 | 281.88 ± 15.59 | 89.74 ± 14.30 | 0.9279 | 6.776E-11 |
| Ada | 1.62 ± 0.85 | 9.59 ± 2.00 | 19.59 ± 4.84 | 3.15 ± 0.61 | 7.83 ± 0.17 | 4.68 ± 1.10 | 1471.86 ± 703.35 | 225.33 ± 75.40 | 0.8874 | 3.79E-08 |
| Uox | 0.14 ± 0.15 | 0.03 ± 0.06 | 0.09 ± 0.08 | 384.58 ± 79.50 | 0 ± 0 | 0.08 ± 0.07 | 0.02 ± 0.03 | 0.084 ± 0.07 | 0.1128 | 0.5999 |
FPKM of genes mainly associated with cell proliferation, apoptosis, and viability and its correlation with the level of uric acid in different rat organs (mean ± SD, n = 3).
| Gene | Stomach | Kidney | Brain | Lung | Liver | Heart | Duodenum | Terminal ileum |
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| Atpaf1 | 11.95 ± 3.43 | 13.11 ± 0.80 | 16.36 ± 2.17 | 6.48 ± 1.23 | 6.93 ± 1.99 | 15.12 ± 1.65 | 12.14 ± 2.04 | 10.72 ± 0.78 | -0.3118 | 0.0972 |
| Atpaf2 | 15.70 ± 1.12 | 16.74 ± 0.49 | 20.09 ± 0.87 | 10.76 ± 1.66 | 8.25 ± 0.59 | 23.01 ± 1.34 | 11.06 ± 2.69 | 11.14 ± 0.70 | -0.6739 | 0.4541 |
| Atp1a1 | 159.40 ± 49.43 | 1164.81 ± 7.36 | 448.52 ± 159.18 | 162.10 ± 12.58 | 126.8 ± 10.27 | 195.50 ± 69.00 | 930.40 ± 133.72 | 849.92 ± 95.97 | 0.3806 | 0.0665 |
| Atp1a2 | 7.61 ± 2.98 | 4.78 ± 0.79 | 311.30 ± 57.23 | 14.52 ± 1.51 | 0.40 ± 0.41 | 63.22 ± 9.10 | 1.44 ± 0.23 | 7.37 ± 3.94 | -0.4183 | 0.0419 |
| Atp1a3 | 0.08 ± 0.06 | 0.10 ± 0.07 | 755.68 ± 95.52 | 3.25 ± 0.31 | 0.05 ± 0.07 | 1.48 ± 1.77 | 0.42 ± 0.15 | 0.48 ± 0.21 | -0.3382 | 0.1060 |
| Atp1a4 | 0 ± 0 | 0.92 ± 0.39 | 0.01 ± 0.01 | 0.05 ± 0.02 | 0 ± 0 | 0.04 ± 0.02 | 0 ± 0 | 0.04 ± 0.02 | -0.2521 | 0.2347 |
| Atp1b1 | 994.36 ± 127.15 | 2309.92 ± 166.22 | 1692.65 ± 175.76 | 101.26 ± 6.09 | 22.01 ± 6.89 | 307.94 ± 43.10 | 1345.89 ± 208.94 | 1265.77 ± 110.33 | -0.0182 | 0.9329 |
| Atp1b2 | 13.91 ± 2.54 | 6.28 ± 0.30 | 358.56 ± 211.59 | 3.79 ± 0.37 | 0.45 ± 0.02 | 12.90 ± 2.95 | 2.93 ± 0.68 | 4.27 ± 0.30 | -0.3207 | 0.1265 |
| Atp1b3 | 54.20 ± 5.53 | 63.09 ± 2.46 | 97.00 ± 16.34 | 169.85 ± 6.17 | 21.31 ± 1.16 | 48.63 ± 4.95 | 46.75 ± 4.69 | 40.10 ± 7.29 | -0.2481 | 0.2425 |
| Atp1b4 | 0 ± 0 | 0.01 ± 0.02 | 0 ± 0 | 1.10 ± 0.05 | 0 ± 0 | 2.73 ± 4.63 | 0.01 ± 0.01 | 0.01 ± 0.01 | -0.2032 | 0.3410 |
| Casp3 | 16.19 ± 4.95 | 4.73 ± 0.55 | 11.00 ± 1.25 | 15.79 ± 0.60 | 12.95 ± 1.30 | 4.96 ± 0.71 | 130.27 ± 27.41 | 41.27 ± 6.77 | 0.9045 | 1.325E-09 |
| MKi67 | 5.29 ± 0.75 | 2.02 ± 0.41 | 0.50 ± 0.06 | 7.23 ± 2.60 | 1.74 ± 0.41 | 1.64 ± 1.11 | 12.99 ± 3.88 | 12.94 ± 2.19 | 0.7768 | 8.067E-06 |
Figure 3Serum uric acid (SUA) in patients with breast tumors (mean ± SD). The level of SUA before treatment in patients with malignant breast tumor (breast cancer) was higher than that in patients with benign breast tumor. (a) Benign group (n = 100) and malignant group (n = 203), P ≤ 0.001, independent samples t-test. When patients with breast cancer are treated with chemotherapeutics, the level of SUA further increased. (b) n = 203, P ≤ 0.001, paired t-test.